Detalles de la búsqueda
1.
Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.
Circulation
; 148(2): 144-158, 2023 07 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37125593
2.
Evaluation of selective inhibitors of 11ß-HSD1 for the treatment of hypertension.
Bioorg Med Chem Lett
; 23(12): 3650-3, 2013 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23659858
3.
Bicyclo[2.2.2]octyltriazole inhibitors of 11ß-hydoxysteroid dehydrogenase type 1. Pharmacological agents for the treatment of metabolic syndrome.
Bioorg Med Chem Lett
; 21(8): 2568-72, 2011 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21421311
4.
A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors.
J Med Chem
; 64(22): 16770-16800, 2021 11 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34704436
5.
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design.
J Med Chem
; 63(22): 13796-13824, 2020 11 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33170686
6.
In Vitro Assays for the Discovery of PCSK9 Autoprocessing Inhibitors.
J Biomol Screen
; 21(10): 1034-1041, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27412534
7.
High-throughput screening of 11beta-hydroxysteroid dehydrogenase type 1 in scintillation proximity assay format.
Assay Drug Dev Technol
; 3(4): 377-84, 2005 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16180992
8.
Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11beta-HSD1: novel therapeutic agents for the treatment of metabolic syndrome.
Bioorg Med Chem Lett
; 15(23): 5266-9, 2005 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16185866
Resultados
1 -
8
de 8
1
Próxima >
>>